PepGen appoints Kasra Kasraian as CTO
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 20 2025
0mins
New Appointment: PepGen (PEPG) has appointed Kasra Kasraian as Chief Technology Officer (CTO), bringing over 25 years of experience in product and process development, CMC strategy, and technical operations.
Previous Experience: Before joining PepGen, Kasraian held various roles at Bluebird Bio (BLUE), where he gained significant expertise in small and large molecules, as well as cell and gene therapies.
Analyst Views on PEPG
Wall Street analysts forecast PEPG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PEPG is 10.00 USD with a low forecast of 3.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
4 Buy
0 Hold
1 Sell
Moderate Buy
Current: 4.990
Low
3.00
Averages
10.00
High
20.00
Current: 4.990
Low
3.00
Averages
10.00
High
20.00
About PEPG
PepGen Inc. is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies. The Company’s Enhanced Delivery Oligonucleotide (EDO) platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases. It is focused on addressing the underlying cause of Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), which have high unmet need. Its pipeline consists of two clinical stage programs, PGN-EDO51 for DMD patients who are amenable to an exon 51-skipping approach and PGN-EDODM1 for DM1 patients, and several additional preclinical stage programs. Its product candidates also include PGN-EDO53, PGN-EDO45 and PGN-EDO44.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
